GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mega Lifesciences PCL (BKK:MEGA-R) » Definitions » Cyclically Adjusted Revenue per Share

Mega Lifesciences PCL (BKK:MEGA-R) Cyclically Adjusted Revenue per Share : ฿17.54 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Mega Lifesciences PCL Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mega Lifesciences PCL's adjusted revenue per share for the three months ended in Mar. 2025 was ฿3.708. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ฿17.54 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Mega Lifesciences PCL's average Cyclically Adjusted Revenue Growth Rate was 5.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Mega Lifesciences PCL was 8.60% per year. The lowest was 8.60% per year. And the median was 8.60% per year.

As of today (2025-07-18), Mega Lifesciences PCL's current stock price is ฿27.08483. Mega Lifesciences PCL's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ฿17.54. Mega Lifesciences PCL's Cyclically Adjusted PS Ratio of today is 1.54.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mega Lifesciences PCL was 4.37. The lowest was 1.51. And the median was 2.77.


Mega Lifesciences PCL Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Mega Lifesciences PCL's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Lifesciences PCL Cyclically Adjusted Revenue per Share Chart

Mega Lifesciences PCL Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 12.79 14.27 14.82 15.93

Mega Lifesciences PCL Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.62 16.31 16.10 15.93 17.54

Competitive Comparison of Mega Lifesciences PCL's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Lifesciences PCL's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mega Lifesciences PCL's Cyclically Adjusted PS Ratio falls into.


;
;

Mega Lifesciences PCL Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mega Lifesciences PCL's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.708/134.9266*134.9266
=3.708

Current CPI (Mar. 2025) = 134.9266.

Mega Lifesciences PCL Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 2.280 100.684 3.055
201509 2.179 100.392 2.929
201512 2.637 99.792 3.565
201603 2.258 100.470 3.032
201606 2.401 101.688 3.186
201609 2.508 101.861 3.322
201612 2.992 101.863 3.963
201703 2.410 102.862 3.161
201706 2.755 103.349 3.597
201709 2.770 104.136 3.589
201712 3.118 104.011 4.045
201803 2.595 105.290 3.325
201806 2.889 106.317 3.666
201809 2.981 106.507 3.776
201812 3.273 105.998 4.166
201903 2.976 107.251 3.744
201906 3.039 108.070 3.794
201909 3.272 108.329 4.075
201912 3.500 108.420 4.356
202003 3.558 108.902 4.408
202006 3.038 108.767 3.769
202009 3.855 109.815 4.737
202012 3.982 109.897 4.889
202103 3.726 111.754 4.499
202106 4.134 114.631 4.866
202109 4.569 115.734 5.327
202112 3.753 117.630 4.305
202203 4.355 121.301 4.844
202206 4.485 125.017 4.841
202209 4.678 125.227 5.040
202212 4.455 125.222 4.800
202303 4.280 127.348 4.535
202306 4.587 128.729 4.808
202309 4.332 129.860 4.501
202312 4.769 129.419 4.972
202403 4.298 131.776 4.401
202406 4.549 132.554 4.630
202409 4.601 133.029 4.667
202412 4.194 133.157 4.250
202503 3.708 134.927 3.708

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Mega Lifesciences PCL  (BKK:MEGA-R) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mega Lifesciences PCL's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=27.08483/17.54
=1.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mega Lifesciences PCL was 4.37. The lowest was 1.51. And the median was 2.77.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mega Lifesciences PCL Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Mega Lifesciences PCL's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Lifesciences PCL Business Description

Industry
Traded in Other Exchanges
Address
Debaratna Road, 909, Ample Tower, 9th Floor, Bangna Nuea, Bangna, Bangkok, THA, 10260
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.

Mega Lifesciences PCL Headlines

No Headlines